Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Immobilized Cell Catalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102719496B reveals immobilized yeast catalysis for (S)-(+)-ethyl mandelate. Offers high ee value, mild conditions, and scalable green manufacturing for global supply chains.
Patent CN102719497B details an immobilized yeast method for high-purity methyl (S)-(+)-mandelate. Offers green manufacturing and cost reduction for chiral intermediates.
Patent CN102191293A reveals a novel immobilized yeast method for high-purity duloxetine intermediates, offering significant cost reduction in API manufacturing and scalable supply chain solutions.
Patent CN119432825A reveals immobilized cell catalysis for lauroyl glycine. Enhances stability and reduces costs for personal care chemical manufacturing supply chains.
Patent CN101205548B reveals immobilized yeast method for high-purity fluoxetine intermediate with superior stereoselectivity and scalability.
Novel immobilized cell method ensures high purity and cost efficiency for pharmaceutical intermediates manufacturing supply chains.
Patent CN107653238A reveals immobilized carbonyl reductase cells for high-yield statin intermediate production, offering significant supply chain stability and cost reduction advantages.
Patent CN104059952A details immobilized cell catalysis for high-purity intermediates. This method offers significant cost reduction and supply chain reliability for global manufacturers.